Janux Therapeutics (NASDAQ:JANX) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 3 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
Analysts have recently evaluated Janux Therapeutics and provided 12-month price targets. The average target is $74.0, accompanied by a high estimate of $100.00 and a low estimate of $42.00. A 3.65% drop is evident in the current average compared to the previous average price target of $76.80.
Interpreting Analyst Ratings: A...
Login or create a forever free account to read this news
Sign up/Log in
